This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

Kaiser Health News Editor-in-Chief Elisabeth Rosenthal joins John Williams to explain how Gilead chooses the price of Remdesivir, with it being the first drug to treat intensive care coronavirus patients.